Medicine and Dentistry
Adenocarcinoma
12%
Adjuvant Therapy
13%
Analysis
33%
Assay
11%
Biological Marker
48%
Cancer Diagnosis
13%
Cancer Recurrence
10%
Cells
17%
Cholangiocarcinoma
10%
Circulating Tumor Cell
81%
Colorectal Cancer
23%
Common Hepatic Artery
10%
Diagnosis
15%
Diseases
11%
Fine-Needle Aspiration
10%
Gastroesophageal Junction
10%
Gastrointestinal Cancer
11%
Gemcitabine
10%
Gene
23%
Hazard Ratio
11%
Hepatocellular Carcinoma
68%
Induction Chemotherapy
10%
Inpatient
23%
Liver Transplantation
18%
Malignant Neoplasm
26%
Metastatic Carcinoma
23%
Needle Biopsy
10%
Neoadjuvant Therapy
18%
Neoplasm
24%
Oncology
21%
Paclitaxel
10%
Pancreas Adenocarcinoma
28%
Pancreas Cancer
41%
Pancreas Islet Cell Tumor
20%
Patient
100%
Polymerase Chain Reaction
10%
Prognosis
15%
Prognostication
14%
Programmed Death 1 Ligand 1
10%
Progressive Disease
10%
Recurrence Free Survival
13%
Recurrent Disease
28%
Scoring System
10%
Somatics
26%
Specimen
10%
Stomach Cancer
10%
Surgery
44%
Survival
21%
Therapeutic Procedure
25%
Tumor Cell
14%
Biochemistry, Genetics and Molecular Biology
Accuracy
13%
Cell Isolation
10%
Chromosome Loss
6%
Electric Potential
16%
Exome Sequencing
5%
GATA6
10%
Gemcitabine
10%
Gene
10%
Gene Amplification
12%
Gene Mutation
6%
Genomics
10%
KRAS
27%
Liquid
15%
Molecule
10%
Mutation
21%
Nested Gene
13%
Next Generation Sequencing
6%
Progression Free Survival
10%
Quality Control
5%
Radiation Beam
10%
Randomized Controlled Trial
10%
Recurrence Free Survival
6%
RNA Sequencing
10%
Sample
6%
Sequencing
31%
Single-Cell Analysis
12%
Staging
24%
Survival
10%
Time
21%
Time
10%
Transcriptome
10%
Transcriptomics
10%
Pharmacology, Toxicology and Pharmaceutical Science
Bile Duct Carcinoma
10%
Biological Marker
28%
Chemotherapy
10%
Colorectal Cancer
13%
Colorectal Liver Metastasis
10%
Digestive System Cancer
10%
Diseases
12%
Gemcitabine
10%
Liver Cell Carcinoma
17%
Liver Cell Carcinoma
10%
Liver Failure
10%
Malignant Neoplasm
10%
Neoplasm
46%
Overall Survival
5%
Paclitaxel
10%
Pancreas Adenocarcinoma
14%
Pancreas Cancer
20%
Programmed Death 1 Ligand 1
10%
Progression Free Survival
7%
Randomized Controlled Trial
10%
Transcription Factor GATA 6
10%
